HSV-2 gD Antibody (910): sc-57860

HSV-2 gD Antibody (910) is a mouse monoclonal IgG1 antibody that detects HSV-2 gD protein of Herpes Simplex Virus 2 by western blotting (WB), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). HSV-2 gD plays a crucial role in the viral entry process, as HSV-2 gD interacts with the Nectin-1 receptor on host cells, facilitating the fusion of the viral envelope with the cell membrane. This interaction is vital for the virus′s ability to infect and spread within the host, making HSV-2 gD a key target for therapeutic interventions and vaccine development. The structure of HSV-2 gD is particularly important, as HSV-2 gD contains specific domains that are essential for binding to its receptors, including the first immunoglobulin-like domain of Nectin-1. Understanding the structural features of HSV-2 gD can provide insights into how the virus evades the immune response and establishes latency, which is critical for developing strategies to combat herpes simplex virus infections. Anti-HSV-2 gD antibody (910) is an invaluable tool for researchers studying the mechanisms of viral entry and pathogenesis, as well as for the development of antiviral therapies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-2 gD Antibody (910) References:

1. Glycoprotein D adjuvant herpes simplex virus vaccine.  |  Bernstein, D. 2005. Expert Rev Vaccines. 4: 615-27. PMID: 16221064
2. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.  |  Wizel, B., et al. 2012. Vaccine. 30: 4361-8. PMID: 22682292
3. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.  |  Wang, K., et al. 2016. J Virol. 90: 562-74. PMID: 26559846
4. Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.  |  Liu, W., et al. 2017. Microbiol Immunol. 61: 176-184. PMID: 28378925
5. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.  |  Du, R., et al. 2017. Antiviral Res. 147: 131-141. PMID: 29061442
6. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.  |  Yan, Y., et al. 2021. mSphere. 6: PMID: 33910988
7. Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.  |  Mahant, AM., et al. 2022. J Infect Dis. 226: 1489-1498. PMID: 35834278
8. Comparison of effects of multiple adjuvants and immunization routes on the immunogenicity and protection of HSV-2 gD subunit vaccine.  |  Wan, M., et al. 2023. Immunol Lett. 260: 11-21. PMID: 37290556
9. Development of recombinant rotavirus carrying herpes simplex virus 2 glycoprotein D gene based on reverse genetics technology.  |  Kawamura, Y., et al. 2024. Microbiol Immunol. 68: 56-64. PMID: 38098134
10. Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy.  |  Atanasiu, D., et al. 2025. Viruses. 17: PMID: 40007004

The preferred HSV-1/2 gD antibody is HSV-1/2 gD Antibody (H170): sc-69802.